No pumping necessary. The price may rise with PoG. This CR is more a move of calculators over investors. Not saying it is fair ..... it just is.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
